Cardiac allograft vasculopathy in Dutch heart transplant recipients

被引:6
|
作者
Galli, G. [1 ,2 ]
Caliskan, K. [1 ]
Balk, A. H. M. M. [1 ]
van Domburg, R. [1 ]
Birim, O. [3 ]
Salerno-Uriarte, J. [2 ]
Manintveld, O. C. [1 ]
Constantinescu, A. A. [1 ]
机构
[1] Erasmus MC, Dept Cardiol, Rotterdam, Netherlands
[2] Univ Insubria, Dept Cardiol, Osped Circolo & Fond Macchi, Varese, Italy
[3] Erasmus MC, Dept Cardiothorac Surg, Rotterdam, Netherlands
关键词
Cardiac allograft vasculopathy (CAV); Donor age; Heart transplantation prognosis; LONG-TERM SURVIVAL; INTERNATIONAL SOCIETY; WORKING FORMULATION; DONOR AGE; NOMENCLATURE; REGISTRY;
D O I
10.1007/s12471-016-0881-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of graft failure after heart transplantation. However, the impact of CAV may vary according to the definition and the regional differences in transplantation settings. Objectives We sought to assess CAV prevalence, predictors and prognosis in Dutch heart transplant recipients based on coronary angiography, following the 2010 standard nomenclature of the International Society for Heart and Lung Transplantation. Methods Patients >= 18 years who underwent heart transplantation at our centre with at least one coronary angiography during follow-up were included in the analysis. Clinical variables were collected prospectively. Results Among 495 analysed recipients, there were 238 (48%) with CAV. The prevalence of CAV was 18, 47 and 70% at 4, 12 and 20 years, respectively. In the multivariable proportional hazards regression analysis, only male donor gender and increasing donor age were significantly associated with the risk of CAV. The long-term prognosis of the patients with CAV at fourth-year angiography was significantly worse as compared with that of CAV-free patients, independently of the severity of CAV (p < 0.001). Conclusion The prevalence of CAV increased gradually over time, with a similar trend as in other registries. Post-transplant survival is decreased in patients with any degree of early CAV, indicating that management strategies should start with donor selection and preventive measures immediately after transplantation.
引用
收藏
页码:748 / 757
页数:10
相关论文
共 50 条
  • [21] Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients
    Szczurek, Wioletta
    Gasior, Mariusz
    Skrzypek, Michal
    Szygula-Jurkiewicz, Bozena
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (10) : 2857 - 2866
  • [22] ASSESSMENT OF CARDIAC ALLOGRAFT VASCULOPATHY IN JAPANESE PEDIATRIC HEART TRANSPLANT RECIPIENTS.
    Kogaki, Shigetoyo
    Fukushima, Norihide
    Takahashi, Kunihiko
    Uchikawa, Toshiki
    Ishii, Ryo
    Higeno, Ryouta
    Ichimori, Hiroaki
    Okada, Yoko
    Ishida, Hidekazu
    Sawa, Yoshiki
    Ozono, Keiichi
    PEDIATRIC TRANSPLANTATION, 2013, 17 (03) : 317 - 317
  • [23] Percutaneous coronary interventions for cardiac allograft vasculopathy in pediatric heart transplant recipients
    Meena, N. K.
    Sachdeva, R.
    Frazier, E. A.
    Sachdeva, R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 372 - 372
  • [24] Cardiac allograft vasculopathy: Differences in de novo and maintenance heart transplant recipients
    Frigerio, Maria
    Garascia, Andrea
    Roubina, Elena
    Distefano, Giada
    Orrego, Pedro Silva
    Colombo, Paola
    Bruschi, Giuseppe
    Vitali, Ettore
    TRANSPLANTATION, 2006, 82 (08) : S5 - S12
  • [25] Coronary interventional procedures in pediatric heart transplant recipients with cardiac allograft vasculopathy
    Shaddy, RE
    Revenaugh, JA
    Orsmond, GS
    Tani, LY
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (11): : 1370 - +
  • [26] The Effect of Medication Regimens on Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients
    Moffett, B. S.
    Hong, B. J.
    Denfield, S. W.
    Humlicek, T. J.
    Cabrera, A. G.
    Price, J. F.
    Dreyer, W. J.
    Jeewa, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S226 - S226
  • [27] Burden of atherogenic lipids and association with cardiac allograft vasculopathy in heart transplant recipients
    Birs, Antoinette S.
    Kao, Andrew S.
    Silver, Elizabeth
    Adler, Eric D.
    Taub, Pam R.
    Wilkinson, Michael J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2025, 19 (01) : 134 - 145
  • [28] OCT Assessment of Allograft Vasculopathy in Heart Transplant Recipients
    Hou, Jingbo
    Lv, Hang
    Jia, Haibo
    Zhang, Shuo
    Xing, Lei
    Liu, Haixia
    Kong, Junying
    Zhang, Shaosong
    Yu, Bo
    Jang, Ik-Kyung
    JACC-CARDIOVASCULAR IMAGING, 2012, 5 (06) : 662 - 663
  • [29] PLACENTA GROWTH FACTOR AS A MARKER OF CARDIAC ALLOGRAFT VASCULOPATHY SEVERITY IN HEART TRANSPLANT RECIPIENTS
    Shevchenko, Olga P.
    Orlova, Olga V.
    Mironkov, Boris L.
    Kazakov, Eduard N.
    Kormer, Arkady J.
    Shevchenko, Alex O.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 266 - 266
  • [30] Cardiac allograft vasculopathy in heart transplant recipients from hepatitis C viremic donors
    Kadosh, Bernard S.
    Birs, Antoinette S.
    Flattery, Erin
    Stachel, Maxine
    Hong, Kimberly N.
    Xia, Yuhe
    Gidea, Claudia
    Aslam, Saima
    Razzouk, Louai
    Saraon, Tajinderpal
    Goldberg, Randal
    Rao, Shaline
    Pretorius, Victor
    Moazami, Nader
    Smith, Deane E.
    Adler, Eric D.
    Reyentovich, Alex
    CLINICAL TRANSPLANTATION, 2024, 38 (04)